UNSPSC 51372024: Cyprenorphine hydrochloride

This classification denotes the hydrochloride form of an opioid receptor agonist with the molecular formula C26H33NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1P6HEG5ZHS, chemically known as 6,14-ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-4,5-epoxy-3-hydroxy-6-methoxy-alpha,alpha-dimethyl-, (5alpha,7alpha)- but more generally known as cyprenorphine, which bears US NIH Compound Identifier 20435.

UNSPSC 51372024 Cyprenorphine hydrochloride is a Commodity code that does not align with the recent state and local opportunities posted under it. The three most recent solicitations — from Seminole County, Florida; Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance — involve naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products, respectively. None of these opportunities explicitly solicits cyprenorphine hydrochloride or opioid agonist medications by that specific name. The code shows little relevant recent activity, and the opportunities tagged to it appear to reflect broader pharmaceutical and community health procurement rather than the specific active pharmaceutical ingredient the code nominally describes.

If the intent is to track opioid-treatment pharmaceuticals or medication-assisted therapy products more broadly, the recent activity reflects state and local health departments, cooperative purchasing alliances, and regional health commissions seeking to manage medication supply chains through authorized wholesalers and direct-manufacturer relationships. The Seminole County IFB (IFB60459723LAS, due July 26, 2023) focused on naloxone and drug deactivation systems for quarterly delivery to community health facilities; the Texas RFI (HHS0017013, closed April 3, 2026) explored direct-to-manufacturer prescription fulfillment models; and the MMCAP RFP (S1070000015802, due March 26, 2026) established multi-state contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, with pricing and compliance evaluated on cGMP and DSCSA standards. The mismatch between the code name and the actual opportunities posted suggests either a cataloging error or a substantial shift in how this code is being applied in practice.